UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Alimentary pharmacology & therapeutics, 2018-07, Vol.48 (1), p.65-77

2018

Volltextzugriff (PDF)

Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism

Alimentary pharmacology & therapeutics, 2012-09, Vol.36 (5), p.449-458

2012

Volltextzugriff (PDF)

Randomised clinical trial: herbal extract HMPL‐004 in active ulcerative colitis – a double‐blind comparison with sustained release mesalazine

Alimentary pharmacology & therapeutics, 2011-01, Vol.33 (2), p.194-202

2011

Volltextzugriff (PDF)

A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

Alimentary pharmacology & therapeutics, 2016-01, Vol.43 (2), p.262-271

2016

Volltextzugriff (PDF)

Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis

Mucosal immunology, 2014-11, Vol.7 (6), p.1492-1503

2014

Volltextzugriff (PDF)

Role of Cytokines in the Pathogenesis of Inflammatory Bowel Disease

Annual review of medicine, 2000-01, Vol.51 (1), p.289-298

2000

Volltextzugriff (PDF)

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

Gut, 2000-10, Vol.47 (4), p.487-496

2000

Volltextzugriff (PDF)

Tumor necrosis factor: Biology and therapeutic inhibitors

Gastroenterology (New York, N.Y. 1943), 2000-10, Vol.119 (4), p.1148-1157

2000

Volltextzugriff (PDF)

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

Gastroenterology (New York, N.Y. 1943), 2000-04, Vol.118 (4), p.705-713

2000

Volltextzugriff (PDF)

High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis

Gut, 2001-11, Vol.49 (5), p.671-677

2001

Volltextzugriff (PDF)

Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor

International Journal of Obesity, 2016-09, Vol.40 (9), p.1424-1434

2016

Volltextzugriff (PDF)

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

The New England journal of medicine, 1997-10, Vol.337 (15), p.1029-1036

1997

Volltextzugriff (PDF)

American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006

Gastroenterology, 2007-07, Vol.133 (1), p.312-339

2007

Volltextzugriff (PDF)

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease

Gastroenterology (New York, N.Y. 1943), 1999-12, Vol.117 (6), p.1278-1287

1999

Volltextzugriff (PDF)

The Role of Thymus-Expressed Chemokine and Its Receptor CCR9 on Lymphocytes in the Regional Specialization of the Mucosal Immune System

The Journal of immunology (1950), 2000-11, Vol.165 (9), p.5069-5076

2000

Volltextzugriff (PDF)

Colonic Bacteria Express an Ulcerative Colitis pANCA-Related Protein Epitope

Infection and Immunity, 2000-03, Vol.68 (3), p.1542-1548

2000

Volltextzugriff (PDF)

Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease

Gastroenterology (New York, N.Y. 1943), 1998-10, Vol.115 (4), p.822-829

1998

Volltextzugriff (PDF)

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Gut, 2006-11, Vol.55 (11), p.1568-1574

2006

Volltextzugriff (PDF)

Long‐term outcomes of thalidomide in refractory Crohn's disease

Alimentary pharmacology & therapeutics, 2015-03, Vol.41 (5), p.429-437

2015

Volltextzugriff (PDF)

Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role

Gut, 1998-06, Vol.42 (6), p.788-791

1998

Volltextzugriff (PDF)

Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes

Alimentary pharmacology & therapeutics, 2007-10, Vol.26 (7), p.1005-1018

2007

Volltextzugriff (PDF)

Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease

Alimentary pharmacology & therapeutics, 2001-04, Vol.15 (4), p.463-473

2001

Volltextzugriff (PDF)

Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

Gastroenterology (New York, N.Y. 1943), 1999-10, Vol.117 (4), p.761-769

1999

Volltextzugriff (PDF)

Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease

Gut, 2000-01, Vol.46 (1), p.58-63

2000

Volltextzugriff (PDF)

Identification of a novel bacterial sequence associated with Crohn's disease

Gastroenterology (New York, N.Y. 1943), 2000-07, Vol.119 (1), p.23-31

2000

Volltextzugriff (PDF)

1 – 25 von 1.279

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.083)
Mit Volltextzugriff
(1.093)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(1.275)
Japanisch
(110)
Koreanisch
(2)
Deutsch
(1)
Türkisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(429)
Humans
(422)
Life Sciences & Biomedicine
(408)
Gastroenterology & Hepatology
(251)
Male
(184)
Female
(183)
Gastroenterology And Hepatology
(162)
Adult
(159)
Biological And Medical Sciences
(150)
Inflammatory Bowel Disease
(144)
Medical Sciences
(128)
Middle Aged
(117)
Immunology
(116)
Ulcerative Colitis
(102)
Crohn's Disease
(87)
Gastroenterology. Liver. Pancreas. Abdomen
(85)
Animals
(83)
Adolescent
(82)
Other Diseases. Semiology
(79)
Stomach. Duodenum. Small Intestine. Colon. Rectum. Anus
(79)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Long‐term efficacy and safety of ustekinumab for Crohn's disease through the second year of therapy

Split-dose administration of thiopurine drugs: a novel and effective strategy for managing preferential 6-MMP metabolism

Randomised clinical trial: herbal extract HMPL‐004 in active ulcerative colitis – a double‐blind comparison with sustained release mesalazine

A validated web‐based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

Inhibition of a novel fibrogenic factor Tl1a reverses established colonic fibrosis

Role of Cytokines in the Pathogenesis of Inflammatory Bowel Disease

Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics

Tumor necrosis factor: Biology and therapeutic inhibitors

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

High level perinuclear antineutrophil cytoplasmic antibody (pANCA) in ulcerative colitis patients before colectomy predicts the development of chronic pouchitis after ileal pouch-anal anastomosis

Cathelicidin suppresses lipid accumulation and hepatic steatosis by inhibition of the CD36 receptor

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21–23, 2006

An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease

The Role of Thymus-Expressed Chemokine and Its Receptor CCR9 on Lymphocytes in the Regional Specialization of the Mucosal Immune System

Colonic Bacteria Express an Ulcerative Colitis pANCA-Related Protein Epitope

Diagnostic accuracy of serological assays in pediatric inflammatory bowel disease

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Long‐term outcomes of thalidomide in refractory Crohn's disease

Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic role

Differences in the management of Crohn’s disease among experts and community providers, based on a national survey of sample case vignettes

Infliximab induces potent anti‐inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn’s disease

Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease

Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease

Identification of a novel bacterial sequence associated with Crohn's disease

Suchergebnisse filtern